Clinical trial
A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)
NCT02567799 is registered in ClinicalTrials.gov with Humanetics Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)
- Lead sponsor
- Humanetics Corporation
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 30, 2015
- Completion date
- September 30, 2020
- Enrollment
- 21 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.